Pablo Corral Highlights CRIC Study: Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in CKD
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on Linkedin:
“Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease
New data from the CRIC study
In CKD patients without clinical CVD, aspirin use was associated with 38% lower MI risk and 28% lower ESRD risk — but only when Lp(a) ≥50 mg/dL.
No significant benefit was seen when Lp(a) <50 mg/dL, and bleeding risk did not increase.”
Title: Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort
Authors: Alexander C. Razavi, Jing Chen, Wei Yang, Daohang Sha, Omar Dzaye, Harpreet S. Bhatia, Sotirios Tsimikas, James P. Lash, Mayank Kansal, Hernan Rincon-Choles, Viola Vaccarino, Terry A. Jacobson, Matthew J. Budoff, Roger S. Blumenthal, Seamus P. Whelton, Laurence S. Sperling, Michael J. Blaha, Jiang H
Read the full article here.
Read more on Hemostasis Today.
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch
-
Feb 23, 2026, 16:36Stéphanie Roullet։ New Method to Explore Primary Haemostasis in Cirrhotic Patients
-
Feb 23, 2026, 16:33Salvatore Massimo Petrina: Top 5 Game-Changers in the AHA and ACC PE Guidelines
-
Feb 23, 2026, 16:21Azin Alizadehasl: Introducing the Second Edition of a New Book on Echocardiography and Cardiac MRI
-
Feb 23, 2026, 16:16Kalyan Roy: When and Why Blood Irradiation Matters in Transfusion Medicine
-
Feb 23, 2026, 15:59Ney Carter Borges: Antithrombotic Therapy in 2025 – A Precision-Based Pharmacologic Update
-
Feb 23, 2026, 15:54Alan Nurden: From Early Discoveries to New Therapeutic Advances in von Willebrand Disease
-
Feb 23, 2026, 15:52Gevorg Tamamyan: Albania’s Vision for the Future of Pediatric Oncology